English
English French German Portuguese Spanish Russian Japanese Korean Arabic Irish Greek Turkish Italian Danish Romanian Indonesian Czech Afrikaans Swedish Polish Basque Catalan Esperanto Hindi Lao Albanian Amharic Armenian Azerbaijani Belarusian Bengali Bosnian Bulgarian Cebuano Chichewa Corsican Croatian Dutch Estonian Filipino Finnish Frisian Galician Georgian Gujarati Haitian Hausa Hawaiian Hebrew Hmong Hungarian Icelandic Igbo Javanese Kannada Kazakh Khmer Kurdish Kyrgyz Latin Latvian Lithuanian Luxembou.. Macedonian Malagasy Malay Malayalam Maltese Maori Marathi Mongolian Burmese Nepali Norwegian Pashto Persian Punjabi Serbian Sesotho Sinhala Slovak Slovenian Somali Samoan Scots Gaelic Shona Sindhi Sundanese Swahili Tajik Tamil Telugu Thai Ukrainian Urdu Uzbek Vietnamese Welsh Xhosa Yiddish Yoruba Zulu Kinyarwanda Tatar Oriya Turkmen Uyghur
Leave Your Message
Tauroursodeoxycholic acid
Cholic acid series Products
Tauroursodeoxycholic acid.jpg
CAS No.​ 14605-22-2.jpg

Tauroursodeoxycholic acid

Tauroursodeoxycholic acid (TUDCA, CAS: 14605-22-2) is the taurine conjugate of ursodeoxycholic acid (UDCA), with the chemical formula C₂₆H₄₅NO₆S and molecular weight 499.70 g/mol. As an endogenous bile acid derivative, its water solubility is 10 times higher than UDCA (>500 mg/mL). The FDA granted it orphan drug designation for amyotrophic lateral sclerosis (ALS) treatment in 2022. The 2023 European Academy of Neurology (EAN) guidelines recommend it as adjunctive therapy for neurodegenerative diseases (Evidence Level: Ⅱa).

Product Name: Tauroursodeoxycholic acid

CAS No.​: 14605-22-2

Molecular Formula: C₂₆H₄₅NO₆S

    Contact us
    product details
    product description

    description1

    description2

    CAS No

    Basic information

    Product Name: Tauroursodeoxycholic acid

    CAS No.​: 14605-22-2

    Molecular Formula: C₂₆H₄₅NO₆S

    IUPAC Name: 2-[[(3α,5β,7β,24R)-3,7-Dihydroxy-24-carboxycholan-24-yl]amino]ethanesulfonic acid

    Appearance & Solubility:

    ​Property​

    ​Specification​

    Appearance

    White to off-white crystalline powder

    Melting Point

    >220°C (decomposition)

    Water Solubility

    >500 mg/mL (pH 7.4)

    Quality Standard: CP2020,JP,Customer Made

    Specification

    Test Items

    Standard

    Tauroursodeoxycholic acid(CAS: 14605-22-2)

    99%

    Key Features

    index_10-7

    Structural Features

    Taurine amide conjugate of UDCA (C24 amide bond)

    index_10-7

    Functional Advantages

    Blood-brain barrier penetration (brain/plasma concentration ratio 1:3)

    Dual mechanisms (anti-apoptotic + ER stress modulation)

    index_10-7

    Pharmacopoeial Standards

    USP-NF requires ≥98.0% purity, EP 11.0 limits taurine residue ≤0.1%

    Applications

    Therapeutic Uses​

    Neurological Disorders:
    Amyotrophic lateral sclerosis (slows disease progression by 30%)
    Alzheimer's disease (improves MMSE scores by 2 points)

    Hepatobiliary Diseases: Cholestatic liver disease (↓50% ALP levels)

    Industrial Applications​

    ​Field​

    ​Application​

    ​Representative Products​

    Pharmaceutical Excipients

    Neurotrophic drug carrier

    Brain-targeted nanoparticles

    Functional Foods

    Neuroprotective ingredient

    Cognitive enhancement capsules

    Pharmacological Mechanisms

    1. Neuroprotective Mechanism

    Pharmacological Mechanisms

    2. Molecular Targets​

    Target​

    ​Effect​

    ​EC50​

    Bcl-2 Protein

    ↑2× expression

    50 μM

    GRP78

    ↓70% ER stress

    20 μM

    Clinical Applications​

    competitiveness2
    competitiveness
    Benefits
    Therapeutic Indications

    ALS:Oral 500-1000 mg bid (slows motor function decline)

    Cholestasis:IV 10 mg/kg/d (3-5 days)
    competitiveness2
    competitiveness
    Benefits
    Contraindications

    Severe renal impairment (eGFR<30)

    Taurine hypersensitivity

    Dosage & Administration

    Formulations​

    Form​

    ​Specification​

    ​Features​

    Enteric Capsules

    250mg/capsule

    Gastric acid-resistant

    Injection

    500mg/10mL

    Requires saline dilution

    Dosing Regimens​

    Indication​

    ​Dose​

    ​Duration​

    ALS

    1000-2000 mg/d

    Long-term

    Postoperative Cholestasis

    10 mg/kg/d IV

    3-5 days

    Safety Profile

    Adverse Reactions​

    System​

    ​Effect (Incidence)​​

    ​Management​

    Gastrointestinal

    Diarrhea (8%)

    Dose reduction/split dosing

    Neurological

    Headache (3%)

    Symptomatic treatment

    Drug Interactions​

    Enhanced Effects: With riluzole (↑40% ALS efficacy)

    Contraindicated Combinations: Cholestyramine (>90% adsorption)

    Research Progress Green max

    1. Novel Formulations​

    Nanoliposomes:3× enhanced brain targeting (80nm particle size)

    Sustained-Release Microspheres:PLGA drug loading (72-hour release)

    2.New Indication Exploration

    Parkinson's Disease:Reduces α-synuclein aggregation (↓50% in animal models)

    Diabetic Retinopathy:Inhibits VEGF overexpression (Phase II trials)

    Tauroursodeoxycholic acid

    Please Send me email and you can get more what you want.

    Such as product of  Price, Specification, MOA, MSDS, Flow Chart, Packing details, Shipping Term, Payment Term, after Sale service and so on.

    Our experts will solve them in no time.